EUCTR2019-001829-26-IT进行中（未招募）1 期
A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients with Relapsing Neuromyelitis Optica Spectrum Disorder. - NA
ALEXION PHARMACEUTICALS INCORPORATED0 个研究点目标入组 15 人开始时间: 2021年1月22日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •assent/consent.
- •Anti-AQP4 Ab-positive and diagnosis of NMOSD as defined by the 2015
- •IPND criteria
- •Historical Relapse Rate of at least 2 relapses in the last 2 years, and
- •with at least 1 relapse in the year prior to Screening.
- •Expanded Disability Status Scale score = 7
- •Patients who enter the study receiving supportive immunosuppressive
- •therapies for the prevention of relapse, either in combination or monotherapy, must be on a stable dosing regimen of adequate duration
- •prior to Screening.
- •Vaccinated against N meningitidis within 3 years prior to, or at the
- •time of initiating eculizumab. Patients who initiate study drug treatment
- •less than 2 weeks after receiving a meningococcal vaccine must receive
- •appropriate prophylactic antibiotics until 2 weeks after the vaccination.
- •Documented vaccination against Hib and S pneumoniae infections 2
- •weeks prior to dosing as per local and country-specific immunization
- •guidelines for the appropriate age group.
- •Willing and capable to give informed assent (if applicable, as
- •determined by the central Institutional Review Boards
- •(IRBs)/Independent Ethics Committees (IECs) and in accordance with
- •local requirements) and whose parent/legal guardian are willing and
- •able to give written informed consent, which includes compliance with
- •the requirements and restrictions listed in the informed consent form
- •(ICF) and in the protocol.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients known to be human immunodeficiency virus (HIV) positive or
- •with congenital immunodeficiency.
- •Unresolved meningococcal or other serious infection.
- •Any unresolved acute or chronic systemic bacterial or other infection
- •which is clinically significant in the opinion of the Investigator and has
- •not been treated with appropriate antibiotics.
- •Hypersensitivity to murine proteins or to one of the excipients of
- •eculizumab.
- •Use of rituximab or other biologicals such as tocilizumab within 6
- •months prior to Screening.
- •Use of mitoxantrone within 3 months prior to Screening.
- •Use of intravenous immunoglobulin (IVIg) or plasma exchange (PE)
- •within 3 weeks prior to Screening.
- •Use of immunomodulatory therapies for multiple sclerosis within 3
- •months prior to Screening.
研究者
相似试验
进行中（未招募）
1 期
A Trial to Evaluate the Safety and Activity of Eculizumab in PediatricPatients with Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)euromyelitis Optica Spectrum Disorder (NMOSD)MedDRA version: 21.1Level: LLTClassification code 10077879Term: Neuromyelitis optica spectrum disorder relapseSystem Organ Class: 100000004852EUCTR2019-001829-26-DEAlexion Pharmaceuticals Inc.12
进行中（未招募）
1 期
A Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients with Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)euromyelitis Optica Spectrum Disorder (NMOSD)MedDRA version: 21.1 Level: LLT Classification code 10077879 Term: Neuromyelitis optica spectrum disorder relapse System Organ Class: 100000004852EUCTR2019-001829-26-ESAlexion Pharmaceuticals Inc.15
进行中（未招募）
不适用
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23-valent Pneumococcal Polysaccharide Vaccine - NDPneumococcal InfectionMedDRA version: 12.1Level: LLTClassification code 10061353Term: Pneumococcal infectionEUCTR2009-011396-77-ITWyeth Research Division on Wyeth Pharmaceuticals Inc.200
进行中（未招募）
不适用
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 68 Years and Older Who Received 1 or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine at Least 3 Years Before Study EnrollmentEUCTR2007-002683-10-DEWyeth Research Division of Wyeth Pharmaceuticals Inc.1,053
进行中（未招募）
不适用
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 68 Years and Older Who Received 1 or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine at Least 3 Years Before Study EnrollmentEUCTR2007-002683-10-SEWyeth Research Division of Wyeth Pharmaceuticals Inc.1,053